Close Menu

NEW YORK ─ BHR Pharmaceuticals and SphingoTec on Tuesday announced that they have inked a distribution agreement for SphingoTec's portfolio of diagnostics products used in acute and critical care applications in the UK and Ireland.

The collaboration in particular focuses on the UK market introduction of Hennigsdorf, Germany-based SphingoTec's point-of-care tests for use of novel biomarkers in critical care, targeting diagnostically underserved conditions such as sepsis, acute heart failure, acute kidney injury, and recently severe COVID-19, the firms said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.